Global Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030
Summary
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.
Peptide Cancer Vaccine segment by Company
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.
Peptide Cancer Vaccine segment by Company
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Peptide Cancer Vaccine Market Size, 2019 VS 2023 VS 2030
1.3 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)
1.4 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)
1.5 Global Peptide Cancer Vaccine Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 GLOBAL PEPTIDE CANCER VACCINE MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 PEPTIDE CANCER VACCINE MARKET BY MANUFACTURERS
3.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
3.2 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
3.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2019-2024)
3.4 Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
3.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
4 PEPTIDE CANCER VACCINE MARKET BY TYPE
4.1 Peptide Cancer Vaccine Type Introduction
4.1.1 ITK-1
4.1.2 GRN-1201
4.1.3 TPIV200
4.1.4 TPIV110
4.1.5 UV1
4.1.6 Galinpepimut-S
4.1.7 TARP 27-35
4.1.8 HER-Vaxx
4.1.9 Vx-001
4.1.10 Others
4.2 Global Peptide Cancer Vaccine Sales by Type
4.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030)
4.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
4.3 Global Peptide Cancer Vaccine Revenue by Type
4.3.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030)
4.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
5 PEPTIDE CANCER VACCINE MARKET BY APPLICATION
5.1 Peptide Cancer Vaccine Application Introduction
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Sales by Application
5.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
5.3 Global Peptide Cancer Vaccine Revenue by Application
5.3.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030)
5.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
6 GLOBAL PEPTIDE CANCER VACCINE SALES BY REGION
6.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Peptide Cancer Vaccine Sales by Region (2019-2030)
6.2.1 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
6.2.2 Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Peptide Cancer Vaccine Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Peptide Cancer Vaccine Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 GLOBAL PEPTIDE CANCER VACCINE REVENUE BY REGION
7.1 Global Peptide Cancer Vaccine Revenue by Region
7.1.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
7.1.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
7.1.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Peptide Cancer Vaccine Revenue (2019-2030)
7.2.2 North America Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Peptide Cancer Vaccine Revenue (2019-2030)
7.3.2 Europe Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Peptide Cancer Vaccine Revenue (2019-2030)
7.4.2 Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Peptide Cancer Vaccine Revenue (2019-2030)
7.5.2 LAMEA Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
8 COMPANY PROFILES
8.1 Boston Biomedical
8.1.1 Boston Biomedical Comapny Information
8.1.2 Boston Biomedical Business Overview
8.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
8.1.5 Boston Biomedical Recent Developments
8.2 Ultimovacs
8.2.1 Ultimovacs Comapny Information
8.2.2 Ultimovacs Business Overview
8.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
8.2.5 Ultimovacs Recent Developments
8.3 BrightPath Biotherapeutics
8.3.1 BrightPath Biotherapeutics Comapny Information
8.3.2 BrightPath Biotherapeutics Business Overview
8.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
8.3.5 BrightPath Biotherapeutics Recent Developments
8.4 TapImmune
8.4.1 TapImmune Comapny Information
8.4.2 TapImmune Business Overview
8.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
8.4.5 TapImmune Recent Developments
8.5 Immatics
8.5.1 Immatics Comapny Information
8.5.2 Immatics Business Overview
8.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
8.5.5 Immatics Recent Developments
8.6 Sellas
8.6.1 Sellas Comapny Information
8.6.2 Sellas Business Overview
8.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
8.6.5 Sellas Recent Developments
8.7 Imugene
8.7.1 Imugene Comapny Information
8.7.2 Imugene Business Overview
8.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
8.7.5 Imugene Recent Developments
8.8 VAXON Biotech
8.8.1 VAXON Biotech Comapny Information
8.8.2 VAXON Biotech Business Overview
8.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
8.8.5 VAXON Biotech Recent Developments
8.9 Generex Biotechnology
8.9.1 Generex Biotechnology Comapny Information
8.9.2 Generex Biotechnology Business Overview
8.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
8.9.5 Generex Biotechnology Recent Developments
8.10 ISA Pharmaceuticals
8.10.1 ISA Pharmaceuticals Comapny Information
8.10.2 ISA Pharmaceuticals Business Overview
8.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
8.10.5 ISA Pharmaceuticals Recent Developments
8.11 OncoTherapy Science
8.11.1 OncoTherapy Science Comapny Information
8.11.2 OncoTherapy Science Business Overview
8.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
8.11.5 OncoTherapy Science Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Peptide Cancer Vaccine Value Chain Analysis
9.1.1 Peptide Cancer Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Peptide Cancer Vaccine Production Mode & Process
9.2 Peptide Cancer Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Peptide Cancer Vaccine Distributors
9.2.3 Peptide Cancer Vaccine Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
1.1 Product Definition
1.2 Global Peptide Cancer Vaccine Market Size, 2019 VS 2023 VS 2030
1.3 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)
1.4 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)
1.5 Global Peptide Cancer Vaccine Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 GLOBAL PEPTIDE CANCER VACCINE MARKET DYNAMICS
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 PEPTIDE CANCER VACCINE MARKET BY MANUFACTURERS
3.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
3.2 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
3.3 Global Peptide Cancer Vaccine Average Sales Price by Manufacturers (2019-2024)
3.4 Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
3.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier
4 PEPTIDE CANCER VACCINE MARKET BY TYPE
4.1 Peptide Cancer Vaccine Type Introduction
4.1.1 ITK-1
4.1.2 GRN-1201
4.1.3 TPIV200
4.1.4 TPIV110
4.1.5 UV1
4.1.6 Galinpepimut-S
4.1.7 TARP 27-35
4.1.8 HER-Vaxx
4.1.9 Vx-001
4.1.10 Others
4.2 Global Peptide Cancer Vaccine Sales by Type
4.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030)
4.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
4.3 Global Peptide Cancer Vaccine Revenue by Type
4.3.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030)
4.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
5 PEPTIDE CANCER VACCINE MARKET BY APPLICATION
5.1 Peptide Cancer Vaccine Application Introduction
5.1.1 Breast Cancer
5.1.2 Lung Cancer
5.1.3 Melanoma
5.1.4 Prostate Cancer
5.1.5 Others
5.2 Global Peptide Cancer Vaccine Sales by Application
5.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
5.3 Global Peptide Cancer Vaccine Revenue by Application
5.3.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030)
5.3.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
6 GLOBAL PEPTIDE CANCER VACCINE SALES BY REGION
6.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Peptide Cancer Vaccine Sales by Region (2019-2030)
6.2.1 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
6.2.2 Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Peptide Cancer Vaccine Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Peptide Cancer Vaccine Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 GLOBAL PEPTIDE CANCER VACCINE REVENUE BY REGION
7.1 Global Peptide Cancer Vaccine Revenue by Region
7.1.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
7.1.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
7.1.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Peptide Cancer Vaccine Revenue (2019-2030)
7.2.2 North America Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Peptide Cancer Vaccine Revenue (2019-2030)
7.3.2 Europe Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Peptide Cancer Vaccine Revenue (2019-2030)
7.4.2 Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Peptide Cancer Vaccine Revenue (2019-2030)
7.5.2 LAMEA Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
8 COMPANY PROFILES
8.1 Boston Biomedical
8.1.1 Boston Biomedical Comapny Information
8.1.2 Boston Biomedical Business Overview
8.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
8.1.5 Boston Biomedical Recent Developments
8.2 Ultimovacs
8.2.1 Ultimovacs Comapny Information
8.2.2 Ultimovacs Business Overview
8.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
8.2.5 Ultimovacs Recent Developments
8.3 BrightPath Biotherapeutics
8.3.1 BrightPath Biotherapeutics Comapny Information
8.3.2 BrightPath Biotherapeutics Business Overview
8.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
8.3.5 BrightPath Biotherapeutics Recent Developments
8.4 TapImmune
8.4.1 TapImmune Comapny Information
8.4.2 TapImmune Business Overview
8.4.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
8.4.5 TapImmune Recent Developments
8.5 Immatics
8.5.1 Immatics Comapny Information
8.5.2 Immatics Business Overview
8.5.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
8.5.5 Immatics Recent Developments
8.6 Sellas
8.6.1 Sellas Comapny Information
8.6.2 Sellas Business Overview
8.6.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
8.6.5 Sellas Recent Developments
8.7 Imugene
8.7.1 Imugene Comapny Information
8.7.2 Imugene Business Overview
8.7.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
8.7.5 Imugene Recent Developments
8.8 VAXON Biotech
8.8.1 VAXON Biotech Comapny Information
8.8.2 VAXON Biotech Business Overview
8.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
8.8.5 VAXON Biotech Recent Developments
8.9 Generex Biotechnology
8.9.1 Generex Biotechnology Comapny Information
8.9.2 Generex Biotechnology Business Overview
8.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
8.9.5 Generex Biotechnology Recent Developments
8.10 ISA Pharmaceuticals
8.10.1 ISA Pharmaceuticals Comapny Information
8.10.2 ISA Pharmaceuticals Business Overview
8.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
8.10.5 ISA Pharmaceuticals Recent Developments
8.11 OncoTherapy Science
8.11.1 OncoTherapy Science Comapny Information
8.11.2 OncoTherapy Science Business Overview
8.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
8.11.5 OncoTherapy Science Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Peptide Cancer Vaccine Value Chain Analysis
9.1.1 Peptide Cancer Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Peptide Cancer Vaccine Production Mode & Process
9.2 Peptide Cancer Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Peptide Cancer Vaccine Distributors
9.2.3 Peptide Cancer Vaccine Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
LIST OF TABLES
Table 1. Peptide Cancer Vaccine Industry Trends
Table 2. Peptide Cancer Vaccine Industry Drivers
Table 3. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 4. Peptide Cancer Vaccine Industry Restraints
Table 5. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 6. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
Table 7. Global Peptide Cancer Vaccine Sales by Manufacturers (K Doses) & (2019-2024)
Table 8. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers
Table 9. Global Peptide Cancer Vaccine Average Sales Price (USD/Dose) of Manufacturers (2019-2024)
Table 10. Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 11. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
Table 13. Global Peptide Cancer Vaccine Manufacturers Commercialization Time
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 16. Major Manufacturers of ITK-1
Table 17. Major Manufacturers of GRN-1201
Table 18. Major Manufacturers of TPIV200
Table 19. Major Manufacturers of TPIV110
Table 20. Major Manufacturers of UV1
Table 21. Major Manufacturers of Galinpepimut-S
Table 22. Major Manufacturers of TARP 27-35
Table 23. Major Manufacturers of HER-Vaxx
Table 24. Major Manufacturers of Vx-001
Table 25. Major Manufacturers of Others
Table 26. Global Peptide Cancer Vaccine Sales by Type 2019 VS 2023 VS 2030 (K Doses)
Table 27. Global Peptide Cancer Vaccine Sales by Type (2019-2024) & (K Doses)
Table 28. Global Peptide Cancer Vaccine Sales by Type (2025-2030) & (K Doses)
Table 29. Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2024)
Table 30. Global Peptide Cancer Vaccine Sales Market Share by Type (2025-2030)
Table 31. Global Peptide Cancer Vaccine Revenue by Type 2019 VS 2023 VS 2030 (K Doses)
Table 32. Global Peptide Cancer Vaccine Revenue by Type (2019-2024) & (K Doses)
Table 33. Global Peptide Cancer Vaccine Revenue by Type (2025-2030) & (K Doses)
Table 34. Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2024)
Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Type (2025-2030)
Table 36. Major Manufacturers of Breast Cancer
Table 37. Major Manufacturers of Lung Cancer
Table 38. Major Manufacturers of Melanoma
Table 39. Major Manufacturers of Prostate Cancer
Table 40. Major Manufacturers of Others
Table 41. Global Peptide Cancer Vaccine Sales by Application 2019 VS 2023 VS 2030 (K Doses)
Table 42. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 43. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 44. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 45. Global Peptide Cancer Vaccine Sales Market Share by Application (2025-2030)
Table 46. Global Peptide Cancer Vaccine Revenue by Application 2019 VS 2023 VS 2030 (K Doses)
Table 47. Global Peptide Cancer Vaccine Revenue by Application (2019-2024) & (K Doses)
Table 48. Global Peptide Cancer Vaccine Revenue by Application (2025-2030) & (K Doses)
Table 49. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 50. Global Peptide Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 51. Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030 (K Doses)
Table 52. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 53. Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 54. Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030) & (K Doses)
Table 55. Global Peptide Cancer Vaccine Sales Forecasted Market Share by Region (2025-2030)
Table 56. North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 57. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 58. North America Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 59. Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 60. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 61. Europe Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 62. Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 63. Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 64. Asia Pacific Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 65. LAMEA Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 66. LAMEA Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 67. LAMEA Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 68. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 69. Global Peptide Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 70. Global Peptide Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 71. Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 72. Global Peptide Cancer Vaccine Revenue Market Share by Region (2025-2030)
Table 73. Boston Biomedical Company Information
Table 74. Boston Biomedical Business Overview
Table 75. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 76. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 77. Boston Biomedical Recent Development
Table 78. Ultimovacs Company Information
Table 79. Ultimovacs Business Overview
Table 80. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 81. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 82. Ultimovacs Recent Development
Table 83. BrightPath Biotherapeutics Company Information
Table 84. BrightPath Biotherapeutics Business Overview
Table 85. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 86. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 87. BrightPath Biotherapeutics Recent Development
Table 88. TapImmune Company Information
Table 89. TapImmune Business Overview
Table 90. TapImmune Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 91. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 92. TapImmune Recent Development
Table 93. Immatics Company Information
Table 94. Immatics Business Overview
Table 95. Immatics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 96. Immatics Peptide Cancer Vaccine Product Portfolio
Table 97. Immatics Recent Development
Table 98. Sellas Company Information
Table 99. Sellas Business Overview
Table 100. Sellas Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 101. Sellas Peptide Cancer Vaccine Product Portfolio
Table 102. Sellas Recent Development
Table 103. Imugene Company Information
Table 104. Imugene Business Overview
Table 105. Imugene Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 106. Imugene Peptide Cancer Vaccine Product Portfolio
Table 107. Imugene Recent Development
Table 108. VAXON Biotech Company Information
Table 109. VAXON Biotech Business Overview
Table 110. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 111. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 112. VAXON Biotech Recent Development
Table 113. Generex Biotechnology Company Information
Table 114. Generex Biotechnology Business Overview
Table 115. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 116. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 117. Generex Biotechnology Recent Development
Table 118. ISA Pharmaceuticals Company Information
Table 119. ISA Pharmaceuticals Business Overview
Table 120. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 121. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 122. ISA Pharmaceuticals Recent Development
Table 123. OncoTherapy Science Company Information
Table 124. OncoTherapy Science Business Overview
Table 125. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 126. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 127. OncoTherapy Science Recent Development
Table 128. Key Raw Materials
Table 129. Raw Materials Key Suppliers
Table 130. Peptide Cancer Vaccine Distributors List
Table 131. Peptide Cancer Vaccine Customers List
Table 132. Research Programs/Design for This Report
Table 133. Authors List of This Report
Table 134. Secondary Sources
Table 135. Primary Sources
Table 1. Peptide Cancer Vaccine Industry Trends
Table 2. Peptide Cancer Vaccine Industry Drivers
Table 3. Peptide Cancer Vaccine Industry Opportunities and Challenges
Table 4. Peptide Cancer Vaccine Industry Restraints
Table 5. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 6. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
Table 7. Global Peptide Cancer Vaccine Sales by Manufacturers (K Doses) & (2019-2024)
Table 8. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers
Table 9. Global Peptide Cancer Vaccine Average Sales Price (USD/Dose) of Manufacturers (2019-2024)
Table 10. Global Peptide Cancer Vaccine Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 11. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
Table 13. Global Peptide Cancer Vaccine Manufacturers Commercialization Time
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 16. Major Manufacturers of ITK-1
Table 17. Major Manufacturers of GRN-1201
Table 18. Major Manufacturers of TPIV200
Table 19. Major Manufacturers of TPIV110
Table 20. Major Manufacturers of UV1
Table 21. Major Manufacturers of Galinpepimut-S
Table 22. Major Manufacturers of TARP 27-35
Table 23. Major Manufacturers of HER-Vaxx
Table 24. Major Manufacturers of Vx-001
Table 25. Major Manufacturers of Others
Table 26. Global Peptide Cancer Vaccine Sales by Type 2019 VS 2023 VS 2030 (K Doses)
Table 27. Global Peptide Cancer Vaccine Sales by Type (2019-2024) & (K Doses)
Table 28. Global Peptide Cancer Vaccine Sales by Type (2025-2030) & (K Doses)
Table 29. Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2024)
Table 30. Global Peptide Cancer Vaccine Sales Market Share by Type (2025-2030)
Table 31. Global Peptide Cancer Vaccine Revenue by Type 2019 VS 2023 VS 2030 (K Doses)
Table 32. Global Peptide Cancer Vaccine Revenue by Type (2019-2024) & (K Doses)
Table 33. Global Peptide Cancer Vaccine Revenue by Type (2025-2030) & (K Doses)
Table 34. Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2024)
Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Type (2025-2030)
Table 36. Major Manufacturers of Breast Cancer
Table 37. Major Manufacturers of Lung Cancer
Table 38. Major Manufacturers of Melanoma
Table 39. Major Manufacturers of Prostate Cancer
Table 40. Major Manufacturers of Others
Table 41. Global Peptide Cancer Vaccine Sales by Application 2019 VS 2023 VS 2030 (K Doses)
Table 42. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)
Table 43. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)
Table 44. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 45. Global Peptide Cancer Vaccine Sales Market Share by Application (2025-2030)
Table 46. Global Peptide Cancer Vaccine Revenue by Application 2019 VS 2023 VS 2030 (K Doses)
Table 47. Global Peptide Cancer Vaccine Revenue by Application (2019-2024) & (K Doses)
Table 48. Global Peptide Cancer Vaccine Revenue by Application (2025-2030) & (K Doses)
Table 49. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 50. Global Peptide Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 51. Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030 (K Doses)
Table 52. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)
Table 53. Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 54. Global Peptide Cancer Vaccine Sales Forecasted by Region (2025-2030) & (K Doses)
Table 55. Global Peptide Cancer Vaccine Sales Forecasted Market Share by Region (2025-2030)
Table 56. North America Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 57. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 58. North America Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 59. Europe Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 60. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 61. Europe Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 62. Asia Pacific Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 63. Asia Pacific Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 64. Asia Pacific Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 65. LAMEA Peptide Cancer Vaccine Sales Growth Rate by Country: 2019 VS 2023 VS 2030 (K Doses)
Table 66. LAMEA Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
Table 67. LAMEA Peptide Cancer Vaccine Sales by Country (2025-2030) & (K Doses)
Table 68. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 69. Global Peptide Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 70. Global Peptide Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 71. Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 72. Global Peptide Cancer Vaccine Revenue Market Share by Region (2025-2030)
Table 73. Boston Biomedical Company Information
Table 74. Boston Biomedical Business Overview
Table 75. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 76. Boston Biomedical Peptide Cancer Vaccine Product Portfolio
Table 77. Boston Biomedical Recent Development
Table 78. Ultimovacs Company Information
Table 79. Ultimovacs Business Overview
Table 80. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 81. Ultimovacs Peptide Cancer Vaccine Product Portfolio
Table 82. Ultimovacs Recent Development
Table 83. BrightPath Biotherapeutics Company Information
Table 84. BrightPath Biotherapeutics Business Overview
Table 85. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 86. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
Table 87. BrightPath Biotherapeutics Recent Development
Table 88. TapImmune Company Information
Table 89. TapImmune Business Overview
Table 90. TapImmune Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 91. TapImmune Peptide Cancer Vaccine Product Portfolio
Table 92. TapImmune Recent Development
Table 93. Immatics Company Information
Table 94. Immatics Business Overview
Table 95. Immatics Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 96. Immatics Peptide Cancer Vaccine Product Portfolio
Table 97. Immatics Recent Development
Table 98. Sellas Company Information
Table 99. Sellas Business Overview
Table 100. Sellas Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 101. Sellas Peptide Cancer Vaccine Product Portfolio
Table 102. Sellas Recent Development
Table 103. Imugene Company Information
Table 104. Imugene Business Overview
Table 105. Imugene Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 106. Imugene Peptide Cancer Vaccine Product Portfolio
Table 107. Imugene Recent Development
Table 108. VAXON Biotech Company Information
Table 109. VAXON Biotech Business Overview
Table 110. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 111. VAXON Biotech Peptide Cancer Vaccine Product Portfolio
Table 112. VAXON Biotech Recent Development
Table 113. Generex Biotechnology Company Information
Table 114. Generex Biotechnology Business Overview
Table 115. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 116. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
Table 117. Generex Biotechnology Recent Development
Table 118. ISA Pharmaceuticals Company Information
Table 119. ISA Pharmaceuticals Business Overview
Table 120. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 121. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
Table 122. ISA Pharmaceuticals Recent Development
Table 123. OncoTherapy Science Company Information
Table 124. OncoTherapy Science Business Overview
Table 125. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Price (USD/Dose), Revenue (US$ Million) and Gross Margin (2019-2024)
Table 126. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
Table 127. OncoTherapy Science Recent Development
Table 128. Key Raw Materials
Table 129. Raw Materials Key Suppliers
Table 130. Peptide Cancer Vaccine Distributors List
Table 131. Peptide Cancer Vaccine Customers List
Table 132. Research Programs/Design for This Report
Table 133. Authors List of This Report
Table 134. Secondary Sources
Table 135. Primary Sources
LIST OF FIGURES
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Peptide Cancer Vaccine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Peptide Cancer Vaccine Sales (2019-2030) & (K Doses)
Figure 5. Global Peptide Cancer Vaccine Average Price (USD/Dose) & (2019-2030)
Figure 6. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. ITK-1 Picture
Figure 9. GRN-1201 Picture
Figure 10. TPIV200 Picture
Figure 11. TPIV110 Picture
Figure 12. UV1 Picture
Figure 13. Galinpepimut-S Picture
Figure 14. TARP 27-35 Picture
Figure 15. HER-Vaxx Picture
Figure 16. Vx-001 Picture
Figure 17. Others Picture
Figure 18. Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 19. Global Peptide Cancer Vaccine Sales Market Share 2019 VS 2023 VS 2030
Figure 20. Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
Figure 21. Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 22. Global Peptide Cancer Vaccine Revenue Market Share 2019 VS 2023 VS 2030
Figure 23. Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
Figure 24. Breast Cancer Picture
Figure 25. Lung Cancer Picture
Figure 26. Melanoma Picture
Figure 27. Prostate Cancer Picture
Figure 28. Others Picture
Figure 29. Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 30. Global Peptide Cancer Vaccine Sales Market Share 2019 VS 2023 VS 2030
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
Figure 32. Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 33. Global Peptide Cancer Vaccine Revenue Market Share 2019 VS 2023 VS 2030
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
Figure 35. North America Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 36. North America Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 37. U.S. Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 38. Canada Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 39. Europe Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 40. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 41. Germany Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 42. France Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 43. U.K. Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 44. Italy Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 45. Netherlands Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 46. Asia Pacific Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 47. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 48. China Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 49. Japan Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 50. South Korea Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 51. Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 52. India Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 53. Australia Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 54. LAMEA Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 55. LAMEA Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 56. Mexico Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 57. Brazil Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 58. Turkey Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 59. GCC Countries Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 60. Global Peptide Cancer Vaccine Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 61. Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 62. North America Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 63. North America Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 64. Europe Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 65. Europe Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 66. Asia-Pacific Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 67. Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 68. LAMEA Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 69. LAMEA Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 70. Peptide Cancer Vaccine Value Chain
Figure 71. Manufacturing Cost Structure
Figure 72. Peptide Cancer Vaccine Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Peptide Cancer Vaccine Market Size (2019-2030) & (US$ Million)
Figure 4. Global Peptide Cancer Vaccine Sales (2019-2030) & (K Doses)
Figure 5. Global Peptide Cancer Vaccine Average Price (USD/Dose) & (2019-2030)
Figure 6. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. ITK-1 Picture
Figure 9. GRN-1201 Picture
Figure 10. TPIV200 Picture
Figure 11. TPIV110 Picture
Figure 12. UV1 Picture
Figure 13. Galinpepimut-S Picture
Figure 14. TARP 27-35 Picture
Figure 15. HER-Vaxx Picture
Figure 16. Vx-001 Picture
Figure 17. Others Picture
Figure 18. Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 19. Global Peptide Cancer Vaccine Sales Market Share 2019 VS 2023 VS 2030
Figure 20. Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
Figure 21. Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 22. Global Peptide Cancer Vaccine Revenue Market Share 2019 VS 2023 VS 2030
Figure 23. Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
Figure 24. Breast Cancer Picture
Figure 25. Lung Cancer Picture
Figure 26. Melanoma Picture
Figure 27. Prostate Cancer Picture
Figure 28. Others Picture
Figure 29. Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 30. Global Peptide Cancer Vaccine Sales Market Share 2019 VS 2023 VS 2030
Figure 31. Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
Figure 32. Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 33. Global Peptide Cancer Vaccine Revenue Market Share 2019 VS 2023 VS 2030
Figure 34. Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
Figure 35. North America Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 36. North America Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 37. U.S. Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 38. Canada Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 39. Europe Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 40. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 41. Germany Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 42. France Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 43. U.K. Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 44. Italy Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 45. Netherlands Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 46. Asia Pacific Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 47. Asia Pacific Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 48. China Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 49. Japan Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 50. South Korea Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 51. Southeast Asia Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 52. India Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 53. Australia Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 54. LAMEA Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 55. LAMEA Peptide Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 56. Mexico Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 57. Brazil Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 58. Turkey Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 59. GCC Countries Peptide Cancer Vaccine Sales and Growth Rate (2019-2030) & (K Doses)
Figure 60. Global Peptide Cancer Vaccine Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 61. Global Peptide Cancer Vaccine Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 62. North America Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 63. North America Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 64. Europe Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 65. Europe Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 66. Asia-Pacific Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 67. Asia-Pacific Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 68. LAMEA Peptide Cancer Vaccine Revenue (2019-2030) & (US$ Million)
Figure 69. LAMEA Peptide Cancer Vaccine Revenue Share by Country: 2019 VS 2023 VS 2030
Figure 70. Peptide Cancer Vaccine Value Chain
Figure 71. Manufacturing Cost Structure
Figure 72. Peptide Cancer Vaccine Production Mode & Process
Figure 73. Direct Comparison with Distribution Share
Figure 74. Distributors Profiles
Figure 75. Years Considered
Figure 76. Research Process
Figure 77. Key Executives Interviewed
